ImmunoPrecise Antibodies (IPA) said Thursday it has entered into a strategic partnership with an unnamed biotechnology company to discover and develop antibody-drug conjugates and bispecific antibodies to treat cancer.
The company said the agreement is valued at $8 million and can be increased to $10 million based on program progression. It will last 18 to 24 months, the company added.
ImmunoPrecise said the partnership will use its B-cell Select platform and artificial intelligence.
Shares of ImmunoPrecise surged past 23% in Thursday's premarket activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.